|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 05:00PM
|
|
Re: Comments re AHA presentation
|
4
|
Resverlogix Corp.
|
Nov 16, 2019 11:17PM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 05, 2018 12:13PM
|
|
Re: eGFR and Cognition?
|
4
|
Resverlogix Corp.
|
Nov 23, 2019 03:28PM
|
|
Re: ACC 2019 Abstracts
|
4
|
Resverlogix Corp.
|
Mar 19, 2019 07:31PM
|
|
Re: CTAD Poster - as posted 12/07/2019
|
4
|
Resverlogix Corp.
|
Dec 08, 2019 12:12PM
|
|
Re: Warrants conversion!
|
4
|
Resverlogix Corp.
|
Nov 26, 2019 10:20AM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
4
|
Resverlogix Corp.
|
Sep 04, 2018 12:33PM
|
|
Re: Not much happening these days regarding share price
|
4
|
Resverlogix Corp.
|
Apr 10, 2019 02:41PM
|
|
Re: RAAS Inhibitors in Patients with Covid-19
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 10:58AM
|
|
Re: Where is the bottom?
|
4
|
Resverlogix Corp.
|
Dec 12, 2019 12:34PM
|
|
Re: Shenzhen Hepalink-Warrants Expiration
|
4
|
Resverlogix Corp.
|
Feb 07, 2022 11:42PM
|
|
Re: BRD2 involvement in Covid19
|
4
|
Resverlogix Corp.
|
Mar 18, 2020 12:14PM
|
|
Multiple endpoints
|
4
|
Resverlogix Corp.
|
Oct 31, 2019 01:47PM
|
|
Re: The synergy of rosuvastatin (Crestor) with apabetalone
|
4
|
Resverlogix Corp.
|
Oct 03, 2019 12:33PM
|
|
Re: Congestive heart failure
|
4
|
Resverlogix Corp.
|
Nov 25, 2019 04:44PM
|
|
Re: MACE Event rate,....
|
4
|
Resverlogix Corp.
|
Feb 28, 2019 12:19PM
|
|
Re: AGMs
|
4
|
Resverlogix Corp.
|
Oct 31, 2019 03:03PM
|
|
Re: eGFR and Cognition?
|
5
|
Resverlogix Corp.
|
Nov 22, 2019 05:16PM
|
|
Re: My general impressions
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 04:11PM
|
